Microbiota-Sensitive Nanocarriers for the Targeted Delivery of Therapeutic Agents into the Gut: Advanced Treatment Strategy for Inflammatory Bowel Disease.

Inflammatory bowel disease (IBD) is a gastrointestinal condition that impacts millions of individuals across the globe, causing recurring inflammation and serious consequences. Traditional treatments, like corticosteroids and immunosuppressants, can cause systemic adverse effects owing to their lack of targeted delivery. Nanotechnology-based techniques, especially microbiota-sensitive nanocarriers, provide a potential route to more effective and targeted treatment. This study aims to explore the potential of microbiota-sensitive nanocarriers to enhance targeted drug delivery for inflammation associated with IBD. Microbiota-sensitive nanocarriers have been established to specifically deliver therapeutic agents in response to changes in pH, redox status, and enzyme activity that occur in the gut. The regulated release of drugs at the target location is ensured by these nanocarriers, as their size and surface features enable them to penetrate the mucus barrier and remain in the inflammatory areas. These minimise negative effects by reducing systemic drug absorption and increasing therapeutic effectiveness via interactions with the gut bacteria. Moreover, such nanocarriers enhance the total bioavailability of the drug and protect it against degradation in the gastrointestinal tract. In conclusion, microbiota-sensitive nanocarriers have tremendous potential for improving IBD treatment outcomes by delivering targeted, localized drug delivery and minimizing adverse effects associated with traditional therapies.